Pharmaceuticals

A breakthrough in oral BTK inhibitors offers multiple sclerosis patients a highly effective treatment without the severe liver risks that doomed rival drugs.

Phase 3 data at ASN Kidney Week reveals lorundrostat's ability to lower blood pressure and albuminuria, positioning Mineralys for a pivotal FDA decision.

Scienture Holdings posted a 256% revenue jump on new drug launches, but scaling its tactical medical defense against synthetic opioids means beating a financial clock.

As its mitochondrial therapeutics near regulatory review, BPGbio appoints M&A expert Jason Krause, signaling a shift toward commercialization or a major exit.

With a new Breakthrough Therapy Designation in China, Ascentage Pharma is targeting the frontline CLL market, challenging established global monopolies.

Laxxon Medical heads to the Jefferies Conference with a 3D-printing platform that could solve the GLP-1 oral delivery puzzle and reinvent patent strategies.

A pending securities class action against Ardelyx highlights the growing collision between lofty biopharma revenue targets and the harsh reality of PBM cost controls.

Gesynta Pharma just shattered enrollment targets for its Phase 2 endometriosis trial. Here is why this signals a massive shift in biotech investment.

French biotech Adocia secures a €7M financing package, lifting its going-concern warning and bridging the gap to a crucial Chinese regulatory approval.

WuXi AppTec just clinched its tenth consecutive Frost & Sullivan award. But can commercial excellence insulate the CRDMO giant from mounting geopolitical friction?

Johnson & Johnson unveils three-year Tremfya data for Crohn's disease, highlighting bold fistula results and framing a new battle over trial reporting.

Enable Injections and Sanofi secure Japan’s first approval for an oncology on-body injector, shifting multiple myeloma treatment from the clinic to the consumer.

As antimicrobial resistance threatens global health, Paratek Pharmaceuticals leverages a $304 million BARDA contract to expand NUZYRA's clinical footprint.

A new monoclonal antibody targeting the root cause of Graves' and thyroid eye disease could upend a market dominated by cumbersome infusions.

As Chinese medicine seeks global credibility, a recent Singapore forum highlights the complex push to translate ancient theory into modern clinical guidelines.

With positive Phase 3 data and an FDA review underway, a novel copper IUD aims to double its lifespan while navigating strict new provider safety mandates.

Cyrano Therapeutics reports positive Phase 2 data for a repurposed asthma drug to treat post-viral smell loss, but regulatory hurdles loom for Phase 3.

Adial Pharmaceuticals appoints the architect behind the first FDA-approved AhR agonist to lead its new ulcerative colitis drug into 2027 clinical trials.

By bringing on a veteran dealmaker with deep isotope supply chain expertise, Actinium is positioning its Ac-225 pipeline for big pharma's aggressive M&A wave.

As biomanufacturing scales to meet global demand, suppliers are locking in profits through recurring consumables and shifting their focus to Asian markets.